A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability

A New Bevacizumab Carrier for Intravitreal Administration: Focus on Stability

Bevacizumab (BVZ) is a monoclonal antibody that binds to human vascular endothelial growth factor A (VEGF-A) and inhibits the interaction between VEGF-A and VEGF receptors, thus blocking the angiogenesis. Repeated intravitreal injections of BVZ for the treatment of ocular pathologies that present an...

Full description

Bibliographic Details
Main Authors: Daniela Chirio, Elena Peira, Simona Sapino, Giulia Chindamo, Simonetta Oliaro-Bosso, Salvatore Adinolfi, Chiara Dianzani, Francesca Baratta, Marina Gallarate
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceutics
Subjects:
lipid nanoparticles
microemulsion
bevacizumab
structure stability
biocompatibility
intravitreal injection
Online Access:https://www.mdpi.com/1999-4923/13/4/560

Internet

https://www.mdpi.com/1999-4923/13/4/560

Similar Items